News

A new study is the first in the U.S. to show that an available generic drug could help people stop using e-cigarettes.

MUSC’s pipeline programs build the skills of underrepresented students and prepare them for careers in health care and medical research.

Leukogene Therapeutics Inc. introduces a promising therapy to treat multiple cancers and hopes to become flagship entity for MUSC’s innovation ecosystem.

A recent MUSC study found that hypertensive disorders of pregnancy may contribute to higher rates of blood clots in women years after delivery.

For people with HIV, the risk of anal cancer varies significantly depending on the region of the country where they live.

MUSC’s ReJoyce Green, Ph.D., leads study highlighted in prestigious publication showing which factors may predict substance use in adolescents.

Renovation for innovation: Blue Sky building on Calhoun to house lab and collaboration space and serve as launch of innovation district.

After melanoma surgery, hairdresser Carol Helton is spreading the word at her hair salon about staying on top of suspicious moles.

Innovation Awareness Month showcases importance of culture at MUSC.

A clinical trial of CAR-T cell therapy developed at Hollings has received NCI funding to expand.